We updated the design of this site on December 18, 2017. Learn more.
ClinicalTrials.gov Menu

Systemic and Local Diffusion of Ethanol After Administration of Ethanol 96% Formulated in a Gel and Ethanol 98% Solution by the Percutaneous Route, in Patients With Congenital Venous Malformations:Pharmacokinetic, Pharmacodynamic and Clinical Study.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT00462462
Recruitment Status : Completed
First Posted : April 19, 2007
Results First Posted : December 12, 2014
Last Update Posted : January 15, 2015
Information provided by (Responsible Party):

Study Description
Brief Summary:

Absolute ethanol has been used "off-label" as an unmodified formulation (solution) in Congenital Venous Malformations (CVM). Despite its effectiveness, absolute ethanol appears difficult to handle because of its high diffusion capacity outside the CVM and in the blood circulation. A less diffusible ethanol-based product (ethanol gel) has been developed in order to minimize systemic and local diffusion capacities of ethanol. Therefore, the pharmacokinetic parameters and their clinical and paraclinical outcomes between ethanol gel 96% and absolute ethanol need to be carried out.

FDA Office of Orphan Products Development (FDA OOPD) : Funding source.

Condition or disease Intervention/treatment Phase
Congenital Venous Malformation Drug: Ethanol 96% Gel Drug: Ethanol 98% Solution Phase 2

Study Design

Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 32 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Official Title: Systemic and Local Diffusion of Ethanol After Administration of Ethanol 96% Formulated in a Gel and Ethanol 98% Solution by the Percutaneous Route, in Patients With Congenital Venous Malformations:Pharmacokinetic, Pharmacodynamic and Clinical Study.
Study Start Date : May 2007
Primary Completion Date : June 2010
Study Completion Date : June 2010
Arms and Interventions

Arm Intervention/treatment
Experimental: 1
Ethanol gel
Drug: Ethanol 96% Gel
Active Comparator: 2
Ethanol solution
Drug: Ethanol 98% Solution

Outcome Measures

Primary Outcome Measures :
  1. Systemic Exposure to Ethanol With the Two Test Products: Determination of the Maximum Plasma Concentration (Cmax) [ Time Frame: Baseline visit (just before and during test product infusion procedure) ]
    Blood samples were performed, just before infusion, then 5 min, 10 min, 20 min, 40 min, 60 min, 90 min, and 120 min after infusion at the first site, then every 60 min onwards until ethanol levels are found under the detection limit. Cmax was estimated directly from experimental data. If all the ethanol concentrations of a patient was below the limit of quantification of the laboratory (LOQ), Cmax was reported as LOQ/2 for this patient.

Secondary Outcome Measures :
  1. Systemic (Cardiopulmonary, Hematological, Metabolic) and Local Outcome of the Two Test Products. [ Time Frame: Study end ]
  2. Change in Volume of Congenital Venous Malformation (CVM) From Screening to Study End (Day 112 Visit). [ Time Frame: Screening and study end (Day 112) ]
  3. Patient Benefit [ Time Frame: study end ]

Eligibility Criteria

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   12 Years and older   (Child, Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Patients of both sexes, of at least 12 years of age,
  • For women of childbearing potential, negative pregnancy test at baseline,
  • Patients with one clinically and radiologically (MRI) documented lesion diagnosed as CVM (pure or predominant),
  • Patients for which an embolosclerotherapy by the percutaneous route is indicated as first line therapy of the test lesion, or for which previous treatments (i.e. surgery, embolosclerotherapy, laser) have been unsuccessful or insufficient,
  • Patients with CVM lesional size of at least 12 cm3 (maximum craniocaudal dimension X mean dimension of 3 transverse equispaced measurements X mean dimension of 3 deepness equispaced measurements dimension) at MRI,
  • Patients with focal or multifocal CVM lesion, i.e. with one or several well-interconnecting venous spaces and well-defined margins,
  • Patients or parents able to follow study instructions and attend study visits,
  • Written informed consent from the patients or parents.

Exclusion criteria:

  • Patients under 12 years of age,
  • Pregnant women, nursing mothers and women of childbearing potential with no reliable contraception from more than 2 months,
  • Women of childbearing potential with a positive pregnancy test at baseline,
  • Patients with CVM of non venous predominance,
  • Patients with CVM that are not reachable by the percutaneous route,
  • Patients with extensive superficial skin CVM (i.e. with high risk of skin necrosis),
  • Patients with a test lesion adjacent to major nerves (e.g. facial nerve in the parotid region, intramuscular regions adjacent to major nerves),
  • Patients with facial CVM or bone involvement,
  • Patients with small CVM lesion (<12 cm3 at MRI),
  • Patients requiring more than 1 ml/Kg body weight (b.w.) in USA or more than 0.5 ml/Kg b.w. in France, or more than 30 mL of absolute ethanol to infuse,
  • Patients with a known allergy to one of the components of the test products,
  • Patients with a suspected allergy to iodinate.ed products,
  • Patients with abnormal clotting parameters (platelets, partial thromboplastin, prothrombin time),
  • Patients with an active inflammatory episode of the test lesion (i.e. acute or subacute swelling of the test lesion),
  • Patients with complex malformations (e.g. Klippel-Trenaunay syndrome, Blue Rubber Bled Nevus syndrome, Muco-cutaneous familial venous malformations, Mafucci's syndrome),
  • Patients in which a surgery, laser therapy or embolosclerotherapy of the test lesion has been performed within the last 12 weeks prior to study entry,
  • Asthmatic patients who require daily medications,
  • Patients with a non treated or non stabilized cardiac disease,
  • Patients with a suspected right-left shunt,
  • Patients with an intercurrent condition or a concomitant treatment which may interfere with a good conduct or the evaluation parameters of the study,
  • Patients who participated in a study within the 12 weeks prior to study entry,
  • Patients or parents who are not able or willing to follow the study instructions,
  • Patients or parents who refuse to give written informed consent.
Contacts and Locations

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00462462

United States, Maryland
Johns Hopkins Medical Institutions
Baltimore, Maryland, United States, 21287
Hôpital Bretonneau Service de neuroradiologie
Tours Cedex 1, France, 37044
Sponsors and Collaborators
FDA Office of Orphan Products Development
Principal Investigator: SALLY E MITCHELL, MD Johns Hopkins Medical Institution (Baltimore, USA)
Principal Investigator: Denis HERBRETEAU, MD Hôpital Bretonneau (Tours, France)
More Information

Responsible Party: Orfagen
ClinicalTrials.gov Identifier: NCT00462462     History of Changes
Other Study ID Numbers: L00122 GI 201 (ORF)
First Posted: April 19, 2007    Key Record Dates
Results First Posted: December 12, 2014
Last Update Posted: January 15, 2015
Last Verified: January 2015

Additional relevant MeSH terms:
Congenital Abnormalities
Pharmaceutical Solutions
Anti-Infective Agents, Local
Anti-Infective Agents
Central Nervous System Depressants
Physiological Effects of Drugs